Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pacira Pharmaceuticals

Share:
Related PCRX
New Biotech ETF From ALPS
Pacira Pharma Reports Changes to EXPAREL Label, Indication Not Affected

In a report published Friday, Jefferies & Company reiterated its Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised its price target from $22.00 to $24.00.

Jefferies noted, “PCRX completed a strong round of financing ($110M ‘convert' at favorable terms) removing a financing overhang – we had modeled cash needs in '13 – and provides a clear runway to profitability in '14. Q4 pre-announced Exparel sales beat estimates and the Exparel commercial metrics bode very well and support our bullish sales estimates. We raise our PT to $24 based on Exparel trends and removal of financing risk.”

Pacira Pharmaceuticals closed on Thursday at $19.43.

Latest Ratings for PCRX

DateFirmActionFromTo
Jan 2015BarclaysMaintainsOverweight
Oct 2014Bank of AmericaDowngradesBuyNeutral
Aug 2014JefferiesMaintainsBuy

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters